Huahai Pharmaceutical announced that the company recently received the “Drug Registration Certificate” for ferrous succinate tablets approved and issued by the State Drug Administration. The dosage form is a tablet, the specification is 0.1 g, and the registration classification is 3 types of chemicals. This drug is used for the prevention and treatment of iron deficiency anemia. It can be considered that it has passed the consistency evaluation for production according to Class 3 chemicals. According to data from the Rice Intranet, the domestic market sales amount of ferrous succinate tablets in 2025 is about RMB 408 million, and the company's total R&D investment in this project is about RMB 5.15 million. The approval of this product further enriches the company's product line.

Huahai Pharmaceutical announced that the company recently received the “Drug Registration Certificate” for ferrous succinate tablets approved and issued by the State Drug Administration. The dosage form is a tablet, the specification is 0.1 g, and the registration classification is 3 types of chemicals. This drug is used for the prevention and treatment of iron deficiency anemia. It can be considered that it has passed the consistency evaluation for production according to Class 3 chemicals. According to data from the Rice Intranet, the domestic market sales amount of ferrous succinate tablets in 2025 is about RMB 408 million, and the company's total R&D investment in this project is about RMB 5.15 million. The approval of this product further enriches the company's product line.